What is the share price of Panacea Biotec Ltd (PANACEABIO) today?
The share price of PANACEABIO as on 5th December 2025 is ₹348.40. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Panacea Biotec Ltd (PANACEABIO) share?
The past returns of Panacea Biotec Ltd (PANACEABIO) share are- Past 1 week: -6.76%
- Past 1 month: -19.20%
- Past 3 months: -14.79%
- Past 6 months: -24.00%
- Past 1 year: -22.76%
- Past 3 years: 145.81%
- Past 5 years: 62.05%
What are the peers or stocks similar to Panacea Biotec Ltd (PANACEABIO)?
The peers or stocks similar to Panacea Biotec Ltd (PANACEABIO) include:What is the market cap of Panacea Biotec Ltd (PANACEABIO) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Panacea Biotec Ltd (PANACEABIO) is ₹2126.63 Cr as of 5th December 2025.What is the 52 week high and low of Panacea Biotec Ltd (PANACEABIO) share?
The 52-week high of Panacea Biotec Ltd (PANACEABIO) is ₹581.90 and the 52-week low is ₹281.10.What is the PE and PB ratio of Panacea Biotec Ltd (PANACEABIO) stock?
The P/E (price-to-earnings) ratio of Panacea Biotec Ltd (PANACEABIO) is -253.77. The P/B (price-to-book) ratio is 2.54.Which sector does Panacea Biotec Ltd (PANACEABIO) belong to?
Panacea Biotec Ltd (PANACEABIO) belongs to the Health Care sector & Biotechnology sub-sector.How to buy Panacea Biotec Ltd (PANACEABIO) shares?
You can directly buy Panacea Biotec Ltd (PANACEABIO) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Panacea Biotec Ltd
PANACEABIO Share Price
348.400.35% (+1.20)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
PANACEABIO Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
PANACEABIO Performance & Key Metrics
PANACEABIO Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -293.73 | 2.54 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.94 | 5.83 | 0.58% |
PANACEABIO Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
PANACEABIO Company Profile
Panacea Biotec Limited is a health management company. The Company's principal business activity is the manufacture of allopathic pharmaceuticals preparations.
BIOCON
PE Ratio
51.17
51.17
1Y Return
2.28%
2.28%
Buy Reco %
70.59
70.59
ANTHEM
PE Ratio
82.39
82.39
1Y Return
9.36%
9.36%
Buy Reco %
66.67
66.67
ONESOURCE
PE Ratio
-1,063.50
-1,063.50
1Y Return
2.47%
2.47%
Buy Reco %
100.00
100.00
SAILIFE
PE Ratio
107.20
107.20
1Y Return
13.45%
13.45%
Buy Reco %
100.00
100.00
ACUTAAS
PE Ratio
88.16
88.16
1Y Return
51.31%
51.31%
Buy Reco %
100.00
100.00
PANACEABIO Forecast
PANACEABIO Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
PANACEABIO
PANACEABIO
Income
Balance Sheet
Cash Flow
Annual Normal View
PANACEABIO Income Statement
PANACEABIO Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 598.59 | 600.78 | 795.34 | 574.08 | 634.86 | 2,348.41 | 614.27 | 621.00 | 615.74 | 672.63 | ||||||||||
Raw Materials | 158.42 | 197.98 | 135.06 | 190.01 | 199.02 | 311.17 | 218.29 | 212.27 | 221.67 | 641.74 | ||||||||||
| Power & Fuel Cost | 30.55 | 33.52 | 34.55 | 29.74 | 30.94 | 37.82 | 31.95 | 35.95 | 38.93 | |||||||||||
| Employee Cost | 148.12 | 151.59 | 147.08 | 142.32 | 156.17 | 182.97 | 126.48 | 149.57 | 173.05 | |||||||||||
| Selling & Administrative Expenses | 86.07 | 68.92 | 94.77 | 83.69 | 75.20 | 102.87 | 70.56 | 70.78 | 86.69 | |||||||||||
| Operating & Other expenses | 73.74 | 57.06 | 179.67 | 88.77 | 88.30 | 39.60 | 110.63 | 110.66 | 64.67 | |||||||||||
EBITDA | 101.69 | 91.71 | 204.21 | 39.55 | 85.23 | 1,673.98 | 56.36 | 41.77 | 30.73 | 30.89 | ||||||||||
| Depreciation/Amortization | 67.95 | 57.28 | 54.00 | 43.22 | 45.59 | 43.78 | 39.12 | 36.71 | 34.81 | 34.13 | ||||||||||
| PBIT | 33.74 | 34.43 | 150.21 | -3.67 | 39.64 | 1,630.20 | 17.24 | 5.06 | -4.08 | -3.24 | ||||||||||
| Interest & Other Items | 100.93 | 100.58 | 104.83 | 173.98 | 185.34 | 180.84 | 4.44 | 3.58 | 3.88 | 5.03 | ||||||||||
| PBT | -67.19 | -66.15 | 45.38 | -177.65 | -145.70 | 1,449.36 | 12.80 | 1.48 | -7.96 | -8.27 | ||||||||||
| Taxes & Other Items | -12.70 | 7.84 | 7.65 | 16.61 | 1.99 | 371.04 | 46.04 | 2.65 | 0.42 | -1.03 | ||||||||||
| Net Income | -54.49 | -73.99 | 37.73 | -194.26 | -147.69 | 1,078.32 | -33.24 | -1.17 | -8.38 | -7.24 | ||||||||||
| EPS | -8.16 | -11.08 | 5.65 | -29.10 | -23.07 | 176.05 | -5.43 | -0.19 | -1.37 | -1.18 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PANACEABIO Company Updates
PANACEABIO Stock Peers
PANACEABIO Past Performance & Peer Comparison
PANACEABIO Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareBiotechnology
Compare valuation on Screener
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Panacea Biotec Ltd | -253.77 | 2.54 | — |
| Biocon Ltd | 51.17 | 1.87 | 0.12% |
| Anthem Biosciences Ltd | 82.39 | 15.43 | — |
| Onesource Specialty Pharma Ltd | -1,063.50 | 3.25 | — |
PANACEABIO Stock Price Comparison
Compare PANACEABIO with any stock or ETFCompare PANACEABIO with any stock or ETF
PANACEABIO
PANACEABIO Holdings
PANACEABIO Shareholdings
PANACEABIO Promoter Holdings Trend
PANACEABIO Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
PANACEABIO Institutional Holdings Trend
PANACEABIO Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
PANACEABIO Shareholding Pattern
PANACEABIO Shareholding Pattern
PANACEABIO Shareholding History
PANACEABIO Shareholding History
Foreign Institutions
Mutual Funds Invested in PANACEABIO
Mutual Funds Invested in PANACEABIO
No mutual funds holding trends are available
Top 1 Mutual Funds holding Panacea Biotec Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0005% | Percentage of the fund’s portfolio invested in the stock 0.05% | Change in the portfolio weight of the stock over the last 3 months 0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 97/124 (+13) |
Compare 3-month MF holding change on Screener
smallcases containing PANACEABIO stock
smallcases containing PANACEABIO stock
Looks like this stock is not in any smallcase yet.
PANACEABIO Events
PANACEABIO Events
PANACEABIO Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
PANACEABIO has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
PANACEABIO Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
PANACEABIO has not given any dividends in last 5 years
PANACEABIO Upcoming Dividends
PANACEABIO Upcoming Dividends
No upcoming dividends are available
PANACEABIO Past Dividends
PANACEABIO Past Dividends
Cash Dividend
Ex DateEx DateSep 19, 2011
Final
Final | Div/Share: ₹0.75
Dividend/Share
₹0.75
Ex DateEx Date
Sep 19, 2011
Cash Dividend
Ex DateEx DateSep 16, 2010
Final
Final | Div/Share: ₹0.25
Dividend/Share
₹0.25
Ex DateEx Date
Sep 16, 2010
PANACEABIO Stock News & Opinions
PANACEABIO Stock News & Opinions
Articles & Videos
Earnings
Panacea Biotec reports consolidated net loss of Rs 13.92 crore in the September 2025 quarter
Net loss of Panacea Biotec reported to Rs 13.92 crore in the quarter ended September 2025 as against net profit of Rs 4.80 crore during the previous quarter ended September 2024. Sales declined 4.22% to Rs 141.13 crore in the quarter ended September 2025 as against Rs 147.35 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales141.13147.35 -4 OPM %-12.614.75 - PBDT-13.5310.67 PL PBT-21.871.99 PL NP-13.924.80 PL Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Spotlight
Panacea Biotech bags vaccine supply deal from PAHO
Easyfive TT provides active immunization against severe diseases namely Diphtheria, Haemophilus influenzae type b, Hepatitis-B, Pertussis, and Tetanus. The company will supply Easyfive TT vaccine during calendar year 2026 and 2027. Panacea Biotec is a research-based biotechnology companies engaged in the business of research, development, manufacture and marketing of vaccines in India and international markets. The company reported consolidated net profit of Rs 4.05 crore in Q1 FY26 as against net loss of Rs 15.80 crore in Q1 FY25. Revenue from operations jumped 44.1% year on year to Rs 166.70 crore in Q1 FY26. The counter declined 2.24% to end at Rs 396.40 on Tuesday, 11 November 2025.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Panacea Biotec to discuss results
Panacea Biotec will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Corporate
Panacea Biotec secures order of Rs 127 cr from CMSS, Govt. of India
Panacea Biotec that the Central Medical Services Society, Ministry of Health and Family Welfare, Government of India (CMSS) has, vide its Letter of Acceptance (LOA) dated 08 October 2025, accepted the Company's offer for supply of bivalent oral polio vaccine (bOPV) against the tender issued by it in this regard. As per the LOA, the Company will supply the vaccine worth Rs.127.20 crore in several tranches over a period of 90 - 480 days from the date of issuance of LOA. Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Panacea Biotec gains after winning Rs 127-cr bOPV supply contract from CMSS
The order, valued at Rs 127.20 crore, will be executed in multiple tranches over a period of 90 to 480 days from the date of issuance of the letter of acceptance (LOA). The contract has been awarded by a domestic entity, and there is no interest of the promoter, promoter group, or group companies in the awarding entity. The transaction does not fall under related party transactions. Panacea Biotec is one of India's leading research-based biotechnology companies engaged in the business of research, development, manufacture and marketing of vaccines in India and international markets. The company reported consolidated net profit of Rs 4.05 crore in Q1 FY26 as against net loss of Rs 15.80 crore in Q1 FY25. Revenue from operations jumped 44.1% year on year to Rs 166.70 crore in Q1 FY26. Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Panacea Biotec wins order of Rs 127 cr
Panacea Biotec announced that the Central Medical Services Society, Ministry of Health and Family Welfare, Government of India ('CMSS') has, vide its Letter of Acceptance (LOA) dated 08 October 2025, accepted the Company's offer for supply of bivalent oral polio vaccine (bOPV) against the tender issued by it in this regard. As per the LOA, the Company will supply the vaccine worth Rs.127.20 crore in several tranches over a period of 90 - 480 days from the date of issuance of LOA. Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Panacea Biotec receives LoA from UNICEF for order worth Rs 315 cr
Panacea Biotec has received a Letter of Award from UNICEF for a Long-Term Agreement for supply of bivalent oral polio vaccine (bOPV) to UNICEF starting from 1st April 2026 to 31st March 2030. The total award to the Company is for supply of bOPV in 10 and 20 vial presentation worth ~US$ 35.65 million (~Rs.315 crore) for a period of Q2 CY2026 and CY2027. Powered by Capital Market - Live
2 months agoCapital Market - Live
Spotlight
Panacea Biotech gains after bagging supply order from UNICEF
The company will supply vaccine in 10 and 20 vial presentations during Q2 CY2026 and CY2027, under an order worth $35.65 million (around Rs 315 crore). Panacea Biotec is engaged in the business of research, development, manufacture, and marketing of branded pharmaceutical formulations in India and international markets. The company reported a consolidated net profit of Rs 4.05 crore in Q1 FY26 compared with net loss of Rs 15.80 crore in Q1 FY25. Net sales jumped 44.1% YoY to Rs 166.70 crore in Q1 FY26.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Panacea Biotec AGM scheduled
Panacea Biotec announced that the Annual General Meeting(AGM) of the company will be held on 30 September 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Panacea Biotec reports consolidated net profit of Rs 4.05 crore in the June 2025 quarter
Net profit of Panacea Biotec reported to Rs 4.05 crore in the quarter ended June 2025 as against net loss of Rs 15.80 crore during the previous quarter ended June 2024. Sales rose 44.05% to Rs 166.70 crore in the quarter ended June 2025 as against Rs 115.72 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales166.70115.72 44 OPM %-0.71-12.09 - PBDT3.63-11.06 LP PBT-4.76-19.79 76 NP4.05-15.80 LP Powered by Capital Market - Live
3 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 1.41%, vs industry avg of 21.23%
Over the last 5 years, market share decreased from 6.29% to 2.58%